Medical Cannabis for Interstitial Cystitis — Switzerland 2026

Interstitial cystitis / bladder pain syndrome is hard to treat in urology. Cannabinoids target neuropathic bladder pain — cheaper for members.

Interstitial cystitis / Bladder Pain Syndrome (BPS) mostly affects women — ~10,000 in Switzerland. Standard therapies (DMSO instillation, amitriptyline, pentosan) are often insufficient. CB1/CB2 receptors in urothelium and pelvic floor modulate pain and inflammation. Tyagi 2014 (preclinical) & cohorts 2019–2023: significant pain and frequency reduction. CannabisClub members: 50 CHF flat instead of 190.

What the studies show

Tyagi 2014 (preclinical): CB2 agonists reduce bladder inflammation and visceral hyperalgesia.

Cohorts 2019–2023 (CPPS/BPS registry): 60 % of IC patients on cannabis report pain and frequency reduction.

Preparations & dosing

CBD oil 25–75 mg twice daily — anti-inflammatory, no high.

THC 2.5–5 mg evenings for sleep disturbance from bladder pain.

Save as a CannabisClub member

Urology/gynecology cannabis consultations cost 190–250 CHF. Members: 50 CHF flat, telemedicine possible. Registration free.

FAQ

Does cannabis replace my DMSO instillations?

No. Add-on in insufficient efficacy. Instillations remain standard in Hunner lesions.

What does membership save?

50 CHF instead of 190 CHF per consultation. Registration free.

Does insurance cover it?

Rarely — BPS is not a standard art. 71a indication. Usually out of pocket.

Cannabis for Interstitial Cystitis — Prescription Switzerland 2026 (Members 50 CHF)